# US 2024/0197952 A1 · Embolization hydrogel having controllable degradation time, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197952 A1
- Document ID: US20240197952A1
- Status: Published application
- Kind: A1
- Application number: 18/286,725
- Filed: 2022-04-28
- Published: 2024-06-20
- Earliest claimed: 2021-04-28
- Assignees: Nextbiomedical Co., Ltd.
- Applicants: Nextbiomedical Co., Ltd.
- Inventors: Don Haeng LEE; Eun Hye LEE; Yi Xian LI; Se Yun KIM; Dae Sung LEE
- Web page: https://patentgrep.com/patent/US20240197952A1

## CPC

- A61L 24/0031: {Hydrogels or hydrocolloids}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/0042: {Materials resorbable by the body}
- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61L 24/08: Polysaccharides {(A61L24/043 takes precedence)}
- A61L 24/102: {Collagen}
- A61L 24/104: {Gelatin}
- A61L 24/108: {Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106}
- A61B 17/1219: {expandable in contact with liquids}
- A61B 2017/00004: {(bio)absorbable, (bio)resorbable or resorptive}
- A61B 2017/00526: {Methods of manufacturing}
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L 2300/406: Antibiotics
- A61L 2300/44: Radioisotopes, radionuclides
- A61L 2300/60: characterised by a special physical form
- A61L 2300/604: Biodegradation
- A61L 2400/04: Materials for stopping bleeding
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present invention relates to: an amorphous of spherical embolisation hydrogel having a degradation time that can be precisely controlled in blood vessels; and a preparation method therefor.

## Claims

### Claim 1

An embolic composition comprising hydrogel microparticles prepared without using a cross-linking agent.

### Claim 2 (depends on 1)

The embolic composition according to claim 1, wherein the hydrogel microparticles are configured such that particles can be produced by thermal denaturation.

### Claim 3 (depends on 1)

The embolic composition according to claim 1, wherein the hydrogel microparticles comprise at least one selected from a biocompatible polymer group consisting of gelatin, collagen, gum, rosin, hyaluronic acid, heparin, dextran, alginic acid, albumin, chitosan, polyglycolide, polylactide, polyhydroxyvalerate, and silk fibroin.

### Claim 4 (depends on 1)

The embolic composition according to claim 1, wherein degradation time in vivo of the hydrogel microparticles is adjusted by heat treatment and/or washing.

### Claim 5 (depends on 4)

The embolic composition according to claim 4, wherein the washing is performed using a solvent with a 8P polar value of 14 or higher.

### Claim 6 (depends on 1)

The embolic composition according to claim 1, wherein the hydrogel microparticles are emulsion type microparticles comprising an organic solvent.

### Claim 7 (depends on 6)

The embolic composition according to claim 6, wherein the organic solvent is at least one selected from a group consisting of methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, hexyl acetate, ethyl formate, dimethyl carbonate, diethyl carbonate, 1,3-dioxolidin-2-one, cellulose acetate butyrate, medium chain triglyceride (MCT) oil, vegetable oil, wax, and infused oil.

### Claim 8 (depends on 6)

The embolic composition according to claim 6, wherein the emulsion comprises no separate emulsifier.

### Claim 9 (depends on 1)

The embolic composition according to claim 1, wherein at least one of a local anesthetic, an antibiotic, and a contrast agent is added.

### Claim 10

A method of preparing hydrogel microparticles prepared through step (a) or step (b):
(a)
1) preparing an aqueous solution of a biocompatible polymer;
2) adding an organic solvent to the aqueous solution of the biocompatible polymer of step 1) so as to be emulsified in order to form micro-sized particles;
3) washing and drying the micro-sized particles prepared in step 2) to obtain micro-sized microparticles;
4) thermally curing the micro-sized microparticles of step 3); and
5) washing, dehydrating, and drying the micro-sized microparticles obtained in step 4); or
(b)
1) preparing an aqueous solution of a biocompatible polymer;
2) stirring and/or low-temperature curing the aqueous solution of the biocompatible polymer of step 1) to form a foam and freeze-drying the foam;
3) thermally curing the foamy material of step 2) to obtain micro-sized microparticles;
4) washing and freeze-drying the micro-sized microparticles obtained in step 3); and
5) crushing the foamy material obtained in step 4) to obtain micro-sized microparticles.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the biocompatible polymer is at least one selected from a group consisting of gelatin, collagen, gum, rosin, hyaluronic acid, heparin, dextran, alginic acid, albumin, chitosan, polyglycolide, polylactide, polyhydroxyvalerate, and silk fibroin.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the organic solvent is at least one selected from a group consisting of methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, hexyl acetate, ethyl formate, dimethyl carbonate, diethyl carbonate, 1,3-dioxolidin-2-one, cellulose acetate butyrate, medium chain triglyceride (MCT) oil, vegetable oil, wax, and infused oil.

### Claim 13 (depends on 10)

The method according to claim 10, wherein cold-curing the micro-sized particles prepared in step 2) at room temperature or lower is added between step 2) of (a) and step 3) of (a).

### Claim 14 (depends on 10)

The method according to claim 10, wherein
crushing the micro-sized microparticles and sieving the crushed microparticles so as to be divided by particle size is further added between step 4) of (a) and step 5) of (a) or after step 5) of (a), or
sieving the micro-sized microparticles so as to be divided by particle size is further added after step 5) of (b).

### Claim 15 (depends on 10)

The method according to claim 10, wherein the thermal curing is performed at 100° C. to 200° C. for 10 minutes to 24 hours.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the washing is performed at a temperature of above 0° C. to 40° C. or lower.

### Claim 17 (depends on 10)

The method according to claim 10, wherein the washing is performed using a solvent with a δP polar value of 14 or higher.

### Claim 18 (depends on 10)

Hydrogel microparticles prepared using the method according to claim 10.

### Claim 19 (depends on 18)

An embolic composition comprising the hydrogel microparticles according to claim 18.

### Claim 20 (depends on 11)

Hydrogel microparticles prepared using the method according to claim 11.
